325 related articles for article (PubMed ID: 29208671)
41. Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.
Scheil-Bertram S; Lorenz D; Ell C; Sheremet E; Fisseler-Eckhoff A
Mod Pathol; 2008 Aug; 21(8):961-7. PubMed ID: 18500268
[TBL] [Abstract][Full Text] [Related]
42. Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.
Linde P; Baues C; Wegen S; Trommer M; Quaas A; Rosenbrock J; Celik E; Marnitz S; Bruns CJ; Fischer T; Schomaecker K; Wester HJ; Drzezga A; van Heek L; Kobe C
Cancer Imaging; 2021 Feb; 21(1):22. PubMed ID: 33579381
[TBL] [Abstract][Full Text] [Related]
43. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
[TBL] [Abstract][Full Text] [Related]
44. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
45. Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma.
Antonioli DA; Wang HH
Gastroenterol Clin North Am; 1997 Sep; 26(3):495-506. PubMed ID: 9309400
[TBL] [Abstract][Full Text] [Related]
46. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Griffiths EA; Pritchard SA; McGrath SM; Valentine HR; Price PM; Welch IM; West CM
Br J Cancer; 2007 May; 96(9):1377-83. PubMed ID: 17437013
[TBL] [Abstract][Full Text] [Related]
47. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
48. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
49. Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma.
Popnikolov NK; Gatalica Z; Adegboyega PA; Norris BA; Pasricha PJ
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):161-5. PubMed ID: 16785783
[TBL] [Abstract][Full Text] [Related]
50. Acidic fibroblast growth factor is expressed sequentially in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Soslow RA; Petersen CG; Remotti H; Altorki N
Dis Esophagus; 2001; 14(1):23-7. PubMed ID: 11422301
[TBL] [Abstract][Full Text] [Related]
51. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
52. A comparative cytopathologic and histologic study of atypia, dysplasia, and adenocarcinoma in Barrett's esophagus.
Geisinger KR; Teot LA; Richter JE
Cancer; 1992 Jan; 69(1):8-16. PubMed ID: 1727677
[TBL] [Abstract][Full Text] [Related]
53. Role of EUS in patients with suspected Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma: impact on endoscopic therapy.
Bartel MJ; Wallace TM; Gomez-Esquivel RD; Raimondo M; Wolfsen HC; Woodward TA; Wallace MB
Gastrointest Endosc; 2017 Aug; 86(2):292-298. PubMed ID: 27889544
[TBL] [Abstract][Full Text] [Related]
54. The sequential model of Barrett's esophagus and adenocarcinoma induced by duodeno-esophageal reflux without exogenous carcinogens.
Sato T; Miwa K; Sahara H; Segawa M; Hattori T
Anticancer Res; 2002; 22(1A):39-44. PubMed ID: 12017320
[TBL] [Abstract][Full Text] [Related]
55. Quantitative analysis of p16 methylation in Barrett's carcinogenesis.
Chueca E; Valero A; Hördnler C; Puertas A; Carrera P; García-González MA; Strunk M; Lanas A; Piazuelo E
Ann Diagn Pathol; 2020 Aug; 47():151554. PubMed ID: 32570024
[TBL] [Abstract][Full Text] [Related]
56. Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.
Hardikar S; Onstad L; Song X; Wilson AM; Montine TJ; Kratz M; Anderson GL; Blount PL; Reid BJ; White E; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2393-403. PubMed ID: 25106775
[TBL] [Abstract][Full Text] [Related]
57. Minute adenocarcinoma on Barrett's esophagus: the importance of directed biopsy sampling.
Sastre Lozano VM; Vicente López JJ; Morán Sánchez S
Rev Esp Enferm Dig; 2019 Feb; 111(2):164. PubMed ID: 30318897
[TBL] [Abstract][Full Text] [Related]
58. Expression profile and cellular localizations of mucin proteins, CK7, and cytoplasmic p27 in Barrett's esophagus and esophageal adenocarcinoma.
Ozcan HEA; Anuk T; Ozden O
Adv Med Sci; 2018 Sep; 63(2):296-300. PubMed ID: 29803118
[TBL] [Abstract][Full Text] [Related]
59. Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis.
Arcidiacono D; Antonello A; Fassan M; Nucci D; Morbin T; Agostini M; Nitti D; Rugge M; Alberti A; Battaglia G; Realdon S
Dig Liver Dis; 2017 Jun; 49(6):630-638. PubMed ID: 28185837
[TBL] [Abstract][Full Text] [Related]
60. Treatment of Barrett's esophagus with high-grade dysplasia.
McAllaster JD; Buckles D; Al-Kasspooles M
Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
